Skip to Content
Merck
CN
All Photos(9)

Documents

Safety Information

ZMS1075

Sigma-Aldrich

Anti-SARS-CoV-1/2 NP Antibody, clone 1C7C7 ZooMAb® Mouse Monoclonal

enhanced validation
greener alternative

recombinant, expressed in HEK 293 cells

Synonym(s):

NC, Nucleocapsid protein, Protein N.

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.43

biological source

mouse (recombinant)

Quality Level

recombinant

expressed in HEK 293 cells

conjugate

unconjugated

antibody form

purified antibody

antibody product type

primary antibodies

clone

1C7C7, recombinant monoclonal

product line

ZooMAb® learn more

form

lyophilized

mol wt

calculated mol wt 45.63 kDa (SARS-CoV-2)
calculated mol wt 46.03 kDa (SARS-CoV)
observed mol wt ~46 kDa

species reactivity

SARS virus

packaging

antibody small pack of 25 μL

greener alternative product characteristics

Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.

enhanced validation

recombinant expression
Learn more about Antibody Enhanced Validation

sustainability

Greener Alternative Product

technique(s)

affinity binding assay: suitable
flow cytometry: 1 μg/mL
immunocytochemistry: suitable
western blot: 1 μg/mL

isotype

IgG2aκ

UniProt accession no.

greener alternative category

shipped in

ambient

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

SARS coronavirus ... N(43740575)
SARS virus ... N(1489678)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Specificity

Clone 1C7C7 is a ZooMAb mouse recombinant antibody that specifically detects SARS-CoV-1/2 NP.

Immunogen

His-tagged full-length recombinant Nucleoprotein from SARS-CoV virus.

Application

Anti-SARS-CoV-1/2 NP, clone 1C7C7 ZooMAb, Cat. No. ZMS1075, is a Mouse monoclonal antibody that detects nucleoprotein from SARS-CoV-1/2 and is tested for use in Affinity Binding Assay, Flow Cytometry, Immunocytochemistry, and Western Blotting.
Flow Cytometry Analysis: 1 mg /ml from a representative lot detected SARS-CoV-1/2 NP in Transfected 293expi cells (Courtesy of Dr Thomas Moran, Center for Therapeutic Antibody Development).

Immunocytochemistry Analysis: 1 μg/mL from a representative lot detected SARS-CoV-1/2 NP in Vero E6 cells infected with SARs-CoV-2 (Courtesy of Dr Ana Fernandez-Sesma Laboratory, Icahn School of Medicine at Mount Sinai (ISMMS), New York).

Western Blotting Analysis: A 1:5,000 dilution of this antibody detected SARS-CoV-1/2 NP in lysate from A549 cells infected with SARS-CoV-2 (Courtesy of Jeff Johnson Laboratory, Icahn School of Medicine at Mount Sinai (ISMMS).

Affinity Binding Assay: This antibody bound recombinant nucleoprotein from SARS-CoV-1/2 with a KD of 4.4 x 10-7 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Target description

Nucleoprotein (UniProt: P59595/P0DTC9; also known as Nucleocapsid protein, NC, Protein N) is encoded by the N gene (Gene ID: 1489678) in Human SARS coronavirus. The SARS-CoV-2 (COVID-19 causing virus) is a positive-strand RNA virus that causes severe respiratory syndrome in human. The mature SARS-CoV-2 contains 4 structural proteins: Envelope (E), Membrane (M), Nucleocapsid (N), and the Spike protein (S). Nucleoprotein of SARS-CoV and SARS-CoV-2 is a homooligomeric protein that packages the positive strand viral genome RNA into helical ribonucleocapsid and plays a role in virion assembly through its interactions with the viral genome and membrane protein M. It plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. The RNA binding region of SARS-CoV and SARS-CoV-2 is localized to amino acids 42-187 and 41-186, respectively. Lack of cysteine is one of the common features in nucleoprotein from different coronaviruses. The complete N protein of SARS-CoV and COV-2 is a highly basic with positive net charges and high pI (10.11). Its N-terminal region is more basic with positive charge, while the C-terminal region is acidic with negative charge. The middle region of nucleoprotein displays relatively higher hydrophobicity and the two termini display greater hydrophilicity. Nucleoprotein can undergo phosphorylation at multiple serines by GSK-3, CKII, Akt, CDKs, and Polo-like kinases. Some of these phosphorylation events are essential for RNA binding, oligomerization and localization to nucleoli. Phosphorylation is also required for recruitment of host RNA helicase DDX1 (DEAD-Box Helicase 1) that facilitates template readthrough and enables longer subgenomic mRNA synthesis. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Physical form

Purified mouse monoclonal antibody IgG2a in buffer containing PBS, 5% Trehalose without preservatives

Reconstitution

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Data presented is the available current product information and provided as-is. These products have not been tested or verified in any additional applications, sample types, including any clinical use. Experimental conditions must be empirically derived by the user. Our Antibody Guarantee only covers tested applications stated herein and conditions presented in our product information and is not extended to publications.

Not finding the right product?  

Try our Product Selector Tool.

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

常规特殊物品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A serological assay to detect SARS-CoV-2 seroconversion in humans.
Amanat, F., et al.
Nature Medicine, 26, 1033-1036 (2020)
J Andrew Duty et al.
Med (New York, N.Y.), 3(10), 705-721 (2022-09-01)
The continual emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern, in particular the newly emerged Omicron (B.1.1.529) variant and its BA.X lineages, has rendered ineffective a number of previously FDA emergency use authorized SARS-CoV-2 neutralizing antibody
Caleb D Swaim et al.
iScience, 24(10), 103213-103213 (2021-10-12)
The emergence of SARS-CoV-2 has led to a global health crisis that, in addition to vaccines and immunomodulatory therapies, calls for the identification of antiviral therapeutics. The papain-like protease (PLpro) activity of nsp3 is an attractive drug target as it
Varun Dwivedi et al.
GeroScience, 46(3), 2901-2913 (2024-02-23)
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still an ongoing global health crisis. Clinical data indicate that the case fatality rate (CFR) is age dependent, with a higher CFR percentage in the elderly
Astha Thakkar et al.
eLife, 12 (2023-03-29)
Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. Many healthcare regulatory agencies recommend administering 'booster' doses of COVID-19 vaccines beyond the standard two-dose series, for this group of patients. Therefore, studying the efficacy of these additional

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service